• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News – India
    • BioMedical
    • BioBusiness
    • BioResearch
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
    • Biotech Express Issues – Access Page
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Editorial: What serious side effects reported after inoculation of Indian COVID-19 vaccines: Survey of AEFI reports
  • COVID-19 scientists are facing an avalanche of abuse, Science survey shows
  • Editorial: Plastic found in human blood – Call an urgency to switch to bioplastic
  • Guestorial: Demand for Nationalization of Healthcare Services in India
  • 19 Year Old Allegedly Dies Post Covishield Vaccination: Kerala High Court Seeks Centre’s Response On Parents’ Plea
  • Phablecare Raises ₹187 Cr In Funding
  • Pfizer Hired 1,800 Additional Employees In 2021 To Process Huge Increase In Vaccine Adverse Events
  • Experts write to PM against WTO proposal on COVID-19 vaccine waivers
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News – India
    • BioMedical
    • BioBusiness
    • BioResearch
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
    • Biotech Express Issues – Access Page
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»The Bharat Biotech’s COVAXIN®Phase-3 Clinical trial report meets WHO’s touchstone

The Bharat Biotech’s COVAXIN®Phase-3 Clinical trial report meets WHO’s touchstone

0
By Biotech Express on July 19, 2021 Articles, Articles- Editorials, BioResearch - Industry, SARS- CoV2 & COVID-19 Updates

G. Baskar*, B. Sangeetha

Department of Biotechnology, St. Joseph’s College of Engineering, Chennai – 600119.
*Corresponding author email: basg2004@gmail.com

Download PDF

COVAXIN® is India’s indigenous COVID-19 vaccine developed by Bharat Biotech Company in association with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). The vaccine is developed via Whole-Virion Inactivated Vero Cell technology. Inactivated vaccines fail to replicate and hence they are improbable to revert and root pathological effects. They comprise dead virus, inept of infecting people but still able to inculcate the immune system to escalate a defensive reaction counter to an infection. COVAXIN® is incorporated along with adjuvants, which are augmented to the vaccine to enhance and boost vaccine’s immunogenicity. The course of vaccination consist of two doses of COVAXIN® administered 28 days apart. This vaccine does not claim for sub-zero storage conditions, stored in multi-dose vials and remain stable at2-8°C which is ready to use without any reconstitution.

Serum Institute of India’s Covishield and Russia’s Sputnik V are the other two Covid-19 vaccines that have been administered to Indian citizens so far. Notably, COVAXIN® has not enlisted in the Emergency-Use Listing (EUL) of World Health Organization (WHO) vaccines due to inadequate data of Phase 3 clinical trials. The lack of endorsement from WHO has been hampering travel plans for individuals as many countries are only accepting vaccines approved by the public health body. However, COVAXIN® has been acknowledgedwith emergency use authorizations in 16 countries together with Brazil, the Philippines, Iran and Mexico.

Finally, the Bharat Biotech company shared the final phase-3 clinical trial pre-print data on medRxiv on 3, July, 2021. According to the data provided, the company recruited 25798 subjects between November 16, 2020 and January 7, 2021(Figure 1). These participants were randomized to BBV152 or placebo groups. The purpose of this study is to gauge the efficacy, safety, and immunogenicity of COVAXIN® in volunteers of and above 18 years. The prime outcome was laboratory-confirmed symptomatic COVID-19, befalling at least fourteen days after the second dose. Ancillary outcomes were efficacy in18≤ 60 years and ≥ 60 years sub-groups and in volunteers with previous stable medical circumstances. The company also assessed safety, reactogenicity and consistency of immune responses for three sequential manufacturing lots.

Out of 24419 participants, 12221 received two doses of BBV152 and 12198 received placebo. In a case-driven analysis, 130 cases of symptomatic COVID-19 were recounted in 16,973 (0·77%) participants with sequelnot less than two weeks after the second vaccination. Out of 130 cases, 24 befell in the vaccine group and 106 in placebo recipients showing an overall vaccine efficacy of 77·8%. Out of 16 cases, one vaccinee and 15 placebo recipients, met the severe symptomatic COVID-19 case characterization demonstrating a vaccine efficacy of 93·4%. Efficacy against asymptomatic COVID-19 was 63·6%. The vaccine conferred 65·2% protection against the SARS-CoV-2 Variant of Concern, B.1.617.2 (Delta) with nil cases of anaphylaxis or vaccine-related deaths. Safety analysis demonstrated that adverse events reported were similar to placebo, with 12% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events. The vaccine has confirmed to neutralize the variants – B.1.1.7 (Alpha) first isolated in UK, P.1- B.1.1.28 (Gamma) & P.2 – B.1.1.28 (Zeta) first isolated in Brazil, B.1.617 (Kappa) first isolated in India, B.1.351 & B.1.617.2 (Beta & Delta) first isolated in RSA & India.

Dr. Soumya Swaminathan (Figure 2), the chief scientist at WHO, revealed to CNBC TV-18 on July,8,2021 that the final phase-3 clinical trial data for COVAXIN® “looks good” and encounters the safety profile of the international public health agency so far. She remarked that although COVAXIN®’s efficacy against the Delta variant of Covid-19 is a bit low, it is still not bad, while the overall efficacy is “quite high.” She said that WHO keeps a close watch on all the vaccines which are on the pipeline for emergency listing, adding that the agency is anticipating more data for a concluding say on the matter.

Figure 2: Dr.Soumya Swaminathan, Chief Scientist at WHO

In the interview, she also affirmed that most parts of the world have seen an uptick in coronavirus cases with no reduction in the number of COVID-related deaths, except in America. She also added that India can take inspiration from countries like the United Kingdom and strive to boost their shots as they are. By the way, she uttered that the WHO still does not recommend booster shots, adding that every country’s prime focus should remain on widening the scope of primary COVID-19 vaccinations.

While on the subject, she also stated that one of the major reasons behind the spike in the number of COVID-related death, in Africa and other nations, is the spread of the Delta variant of the SARS-COV-2 that was first found in India. Listing out the reason for worry, she said the original strain could infect three people, the Delta variant can infect 6-8 and added that the world could witness another surge in coronavirus cases if the virus mutates further.

Last of all, she emphasized the need for social distancing and the usage of face masks. She pronounced that even after 70 percent of a nation’s population is vaccinated, the remaining 30 percent stay at rest. In the end, the WHO Chief Scientist, Soumya Swaminathan concluded that vaccines alone are not enough and the government needs to continue with the testing and tracking method.

After the pre-print submission, Dr. N. K. Arora, Chief of National Technical Advisory Group on Immunisation, India (NTAGI, India) (Figure 3), supposed that these results will aid the vaccine to get acknowledgement from the WHO and people who have been administered COVAXIN® in our country will be capable of travelling across the globe without any restraints.

Figure 3: Dr. N. K. Arora, Chief of National Technical Advisory Group on Immunisation, India. (NTAGI, India)

Amidst unease over the lack of international recognition for locally manufactured  COVAXIN®, the statement given by the Chief Scientist, Dr Soumya Swaminathan, emerge as a budding outbreath of liberation for students, officials and others who meant to travel abroad.

Published in July 2021 Issue

Sources:
1. https://www.bharatbiotech.com/covaxin.html
2. https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1.full-text.
3. https://www.livemint.com/news/india/who-approval-for-covaxin-soon-chief-scientist-says-data-meets-benchmark-11625800595673.html

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Editorial: What serious side effects reported after inoculation of Indian COVID-19 vaccines: Survey of AEFI reports

Editorial: Plastic found in human blood – Call an urgency to switch to bioplastic

Guestorial: Demand for Nationalization of Healthcare Services in India

Leave A Reply Cancel Reply

Current Issue – April 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Editorial: What serious side effects reported after inoculation of Indian COVID-19 vaccines: Survey of AEFI reports April 25, 2022
  • COVID-19 scientists are facing an avalanche of abuse, Science survey shows April 24, 2022
  • Editorial: Plastic found in human blood – Call an urgency to switch to bioplastic April 24, 2022
  • Guestorial: Demand for Nationalization of Healthcare Services in India April 24, 2022
  • 19 Year Old Allegedly Dies Post Covishield Vaccination: Kerala High Court Seeks Centre’s Response On Parents’ Plea April 15, 2022
  • Phablecare Raises ₹187 Cr In Funding April 11, 2022
  • Pfizer Hired 1,800 Additional Employees In 2021 To Process Huge Increase In Vaccine Adverse Events April 9, 2022
  • Experts write to PM against WTO proposal on COVID-19 vaccine waivers April 8, 2022
  • Bose Institute Scientists earn retraction due to manipulation April 5, 2022
  • WHO suspends Covaxin supply to UN agencies April 4, 2022
  • Lockdowns, Not the Pandemic, Created Havoc April 1, 2022
  • WHO selects Biological E to transfer mRNA COVID vaccine tech April 1, 2022
  • Dr. Reddy’s Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany April 1, 2022
  • New Zealand High Court ENDS Vaccine Mandate: “It’s a Gross Violation of Human Rights” April 1, 2022
  • S&T Ministry to support startup in medical implants March 31, 2022
  • FDA Clears Marketing of Genome-Edited Beef Cattle March 30, 2022
  • Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey March 30, 2022
  • Undisclosed industry payments rampant in drug-trial papers in Australia March 29, 2022
  • Fraud Trial of Former Theranos Executive Ramesh’ Sunny’ Balwani Begins March 29, 2022
  • Substandard, fake medical products increased by almost 47% from 2020 to 2021 during pandemic: report March 29, 2022
  • Editorial: Biofuels in India – a perfect waste to wealth and net zero emission energy option March 29, 2022
  • Bharat Biotech and BIOFABRI partner to develop, manufacture and distribute novel TB vaccine March 28, 2022
  • Fibroheal raises debt funding from BIRAC March 28, 2022
  • Editorial – Energy, Renewable Energy and Bioenergy March 28, 2022
  • IISc, India to set up public health centre with Rs105 cr funding from philanthropist March 27, 2022
  • Tamil Nadu makes scientifically dubious claim on vaccines in the Supreme Court March 27, 2022
  • Guest Article: GENE EDITED-CRISPERED FLOWERS: Blooming with grace March 27, 2022
  • Dr. Anthony Fauci, Biden admin operated with missing data as CDC issued pandemic guidance, emails show March 25, 2022
  • Contents – February 2022 March 3, 2022
  • Drs Ella deserve Padma Award for their innovations and management in biotechnology: India’s pioneer recombinant biologist Prof Ramareddy Guntaka February 26, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • Articles- News Reports
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • BioResearch – Industry
  • Biotech – Agriculture
  • Biotech – Healthcare
  • Biotech – Supplies
  • Biotech News – Featured
  • Biotech News – India
  • Biotech News – Industry
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.